Literature DB >> 20955828

Hepatitis A and travel amongst Nova Scotia postsecondary students: evidence for a targeted vs. universal immunization strategy.

Katherine Matheson1, Beth Halperin, Shelly McNeil, Joanne M Langley, Donna Mackinnon-Cameron, Scott A Halperin.   

Abstract

BACKGROUND: Canadian guidelines recommend hepatitis A virus (HAV) vaccination for high-risk persons, such as travelers to HAV-endemic areas. The US CDC advocates universal immunization.
OBJECTIVES: To explore whether a universal strategy for HAV immunization rather than the Canadian targeted approach for travelers is justified by measuring compliance of postsecondary students with Canadian guidelines.
METHODS: A cross-sectional study using an electronic survey method elicited HAV risk factors, immunization history, disease status, and factors affecting immunization status from postsecondary students. Seropositivity was determined by measuring HAV antibodies in saliva from a convenience sample of survey participants within each study group. Statistical analysis used Fisher's exact test and logistic regression.
RESULTS: We received 2279 completed surveys (10.6% response) and 235 saliva samples (58.7% response). A total of 1380 (60.6%) participants had traveled to HAV-endemic regions and 1851 (81.2%) were planning to do so within the next 5 years. Less than half who traveled to HAV-endemic areas reported a history of HAV vaccination (48.0%). HAV seropositivity rates were higher amongst those who traveled to (63.6%) or were planning to travel to (55.0%) HAV-endemic areas than those who had never traveled or had no plans to travel to such areas (17.4%). Only 8.9% of unvaccinated students were seropositive (5.3% of Canadian-born students). Amongst unvaccinated, seropositive students, there was a nonsignificant trend for higher seropositivity in those who had previously traveled to HAV-endemic areas (14.7%) than those who had not traveled abroad (4.4%), suggesting an exposure to HAV during travel. Nearly all (96.5%) unvaccinated students, who were willing to be vaccinated based on current knowledge or if their doctor recommended it, indicated a willingness to receive vaccine if it were provided free of charge.
CONCLUSIONS: Current Canadian guidelines for HAV vaccination are not being followed within the postsecondary student population. Given high rates of travel to HAV-endemic areas in this population, a universal approach to HAV vaccination may be warranted.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20955828     DOI: 10.1016/j.vaccine.2010.09.107

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Changes in the epidemiology of hepatitis A outbreaks 13 years after the introduction of a mass vaccination program.

Authors:  Ana Martínez; Sonia Broner; M Rosa Sala; Sandra Manzanares-Laya; Pere Godoy; Caritat Planas; Sofia Minguell; Nuria Torner; Mireia Jané; Angela Domínguez; The Working Group For The Study Of The Immune Status In Health Care; For The Study Of Hepatitis A In Catalonia
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

2.  Travel risk behaviours and uptake of pre-travel health preventions by university students in Australia.

Authors:  Anita E Heywood; Meng Zhang; C Raina MacIntyre; Holly Seale
Journal:  BMC Infect Dis       Date:  2012-02-17       Impact factor: 3.090

Review 3.  Challenges to mapping the health risk of hepatitis A virus infection.

Authors:  Khayriyyah Mohd Hanafiah; Kathryn H Jacobsen; Steven T Wiersma
Journal:  Int J Health Geogr       Date:  2011-10-18       Impact factor: 3.918

4.  Longitudinal Study of Hepatitis A Infection by Saliva Sampling: The Kinetics of HAV Markers in Saliva Revealed the Application of Saliva Tests for Hepatitis A Study.

Authors:  Luciane Almeida Amado Leon; Adilson José de Almeida; Vanessa Salete de Paula; Renata Santos Tourinho; Daniel Antunes Maciel Villela; Ana Maria Coimbra Gaspar; Lia Laura Lewis-Ximenez; Marcelo Alves Pinto
Journal:  PLoS One       Date:  2015-12-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.